Celgene to collaborate with tiny Jounce on cancer immunotherapy


Privately held Jounce Therapeutics Inc, which is working on treatments designed to use a patients' own immune systems to better attack cancer, said on Tuesday it had entered into an collaboration and investment agreement with Celgene Corp worth more than $2.5 billion. The deal for the tiny Cambridge, Massachusetts-based company comes just at little more than three years after it was launched with funding from life sciences investor Third Rock Ventures.



from Biotech News